ImmunityBio, Inc. (IBRX)
NASDAQ · Healthcare
ImmunityBio, Inc. Operating Income 2013–2025
ImmunityBio, Inc. annual/quarterly operating income history and growth rate from 2014 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- ImmunityBio, Inc. operating income for the quarter ending March 31, 2026 was -69.8 M, a 8.32% increase year-over-year.
- ImmunityBio, Inc. operating income for the twelve months ending March 31, 2026 was -261.1 M, a 26.42% decrease year-over-year.
- ImmunityBio, Inc. annual operating income for 2025 was -256.0 M, a 25.61% decrease from 2024.
- ImmunityBio, Inc. annual operating income for 2024 was -344.2 M, a 4.99% decrease from 2023.
- ImmunityBio, Inc. annual operating income for 2023 was -362.3 M, a 3.12% increase from 2022.
- ImmunityBio, Inc. annual operating income for 2022 was -351.3 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
ImmunityBio, Inc. Operating Income — FAQ
ImmunityBio, Inc. (IBRX) operating income over the last 13 years — annual and quarterly figures with year-over-year growth and charts.
What is ImmunityBio, Inc.'s operating income?
ImmunityBio, Inc. (IBRX) reported operating income of -$256M for fiscal 2025.
Where can I see IBRX's operating income history?
The chart and table above show ImmunityBio, Inc.'s operating income by year and by quarter, including the growth rate.